Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 214 от 240

Активно (без набиране)

Vibrotactile Coordinated Reset: A Non-invasive Treatment for Parkinson's Disease 2

Parkinson Disease

The purpose of our study is to evaluate Vibrotactile Coordinated Reset stimulation (vCR) and its effects on motor function in people with Parkinson's disease (PD). vCR will be administered with a device called the Vibrotactile (VT) Touch device. vCR can be used in conjunction with medication and is expected to delay the need to increase dopamine medication. It also provides a more flexible alternative to deep brain stimulation (DBS) in that the vCR therapy can be easily stopped or modified to better suit the patients' needs.

Начало: 12.07.2023 Край: 01.11.2026 Възраст: 45–85 г.

United States Synergic Medical Technologies, Inc. NCT05881460

Активно (без набиране) Фаза 1/2

To Evaluate the Safety and Efficacy of GS1191-0445 Injection in the Treatment of Severe Hemophilia A

Severe Hemophilia A

This study is a single-arm, open-label study evaluating the safety and efficacy of GS1191-0445 injection as a single dose in Chinese subjects with severe hemophilia A. GS1191-0445 is an adeno-associated virus 8 (AAV8)-delivered gene therapy designed to express B-domain deleted human factor VIII (FVIII) under the regulation of a human liver-specific promoter. Following a single intravenous administration, AAV8 gene expression cassette, which transfects hepatocytes and facilitates the specific expression and secretion of FVIII into the blood.

Начало: 10.07.2023 Край: 23.12.2029 Възраст: 18–65 г.

China Gritgen Therapeutics Co., Ltd. NCT07548411

Активно (без набиране) Фаза 3

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

Obesity

This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).

Начало: 07.07.2023 Край: 07.12.2026 Възраст: 6–18 г.

Austria, Belgium, Denmark +7 Novo Nordisk A/S NCT05726227

Активно (без набиране) Фаза 2

Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders

Schizophrenia Treatment Resistant Depression Aging, Premature

This pilot open-label study examines the effects of a combination of dasatinib plus quercetin - two drugs that have known senolytics properties - on physiological aging in older individuals with depression or schizophrenia.

Начало: 01.07.2023 Край: 01.10.2027 Възраст: от 50 г.

United States Washington University School of Medicine NCT05838560

Активно (без набиране) Ранна Фаза 1

Ozone Oil-based Gel and CHX Gel After Lower Third Molar Removal

Pain and Dry Soket

Overall, 100 patients of both genders were included in the study, with indication of surgical extraction of lower third molar, positioned similarly after being clinically and radiographically checked by X-ray and orthopantomography. Each patient was subjected to both groups in separate sessions: treated with ozone gas and with CHX gel 1%. Data on pain intensity, number of taken analgesics- painkillers, and dry socket were recorded for 48 h and at Day 7

Начало: 01.07.2023 Край: 01.09.2026 Възраст: 21–35 г.

Egypt Cairo University NCT07549672

Активно (без набиране) Фаза 3

Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis gMG

The primary purpose of this study is to characterize the pharmacokinetics and pharmacodynamics of treatment with ravulizumab intravenous infusion in pediatric participants with gMG.

Начало: 24.06.2023 Край: 30.06.2028

Italy, Japan, Serbia +2 Alexion Pharmaceuticals, Inc. NCT05644561

Активно (без набиране)

Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)

Heart Failure

Early Feasibility Study of the NORM™ System in Heart Failure Patients

Начало: 19.06.2023 Край: 01.12.2027 Възраст: от 18 г.

United States Foundry Innovation & Research 1, Limited (FIRE1) NCT05763407

Активно (без набиране)

Evaluation of the Use of a Remote Monitoring and Follow-up Option for Patients With Chronic Obstructive Pulmonary Disease (BOREAL)

Chronic Obstructive Pulmonary Disease

The purpose of this study is to evaluate the ability of the Bora Care remote monitoring solution to detect early acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD).

Начало: 19.06.2023 Край: 29.06.2026 Възраст: от 18 г.

France Assistance Publique - Hôpitaux de Paris NCT05759247

Активно (без набиране)

Analysis of Medial Clear Space Widening in Weber B Ankle Fractures

Weber B Ankle Fractures

The investigators purpose of this study is to obtain all three standard of care stress views of the ankle (gravity stress, manual stress, weightbearing stress) to compare the amount of tibiotalar joint instability predicted by each to determine if there are significant differences measured by the differing stress techniques.

Начало: 25.05.2023 Край: 01.05.2027 Възраст: 18–90 г.

United States University of Utah NCT07028944

Активно (без набиране) Фаза 2

An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis

Rheumatoid Arthritis

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid arthritis (RA).

Начало: 23.05.2023 Край: 01.04.2026 Възраст: от 18 г.

Argentina, Czechia, France +7 Eli Lilly and Company NCT05848258

Активно (без набиране)

PA Moves Trial - Patient Participants

Overweight or Obesity Diabetes Mellitus, Type 2 Physical Inactivity

The purpose of this study is to address physical inactivity in rural populations in Pennsylvania.

Начало: 23.05.2023 Край: 01.12.2027 Възраст: 18–75 г.

United States University of Pittsburgh NCT05227105

Активно (без набиране) Фаза 2

Oral Glibenclamide in Preterm Infants With Hyperglycaemia (GALOP)

Transient; Hypoglycemia, Neonatal Preterm Glibenclamide Adverse Reaction

The purpose of this study is to confirm hypothesis that Glibenclamide can be administered orally and is an alternative to insulin therapy in treating transient hyperglycemia of premature newborns.

Начало: 20.05.2023 Край: 30.04.2026 Възраст: до 34 г.

France Assistance Publique - Hôpitaux de Paris NCT05687500

Активно (без набиране) Фаза 2

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Metastatic Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.

Начало: 19.05.2023 Край: 01.11.2027 Възраст: от 18 г.

Brazil, Bulgaria, Georgia +3 Stemline Therapeutics, Inc. NCT05596409

Активно (без набиране) Фаза 2

Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer

NSCLC Neoadjuvant Therapy

China with high incidence of non-small cell lung cancer. In the past few decades, surgery, radiotherapy, chemotherapy and other treatments were continuously improved, however, the mortality of lung cancer patients was not significantly decreased. For patients with locally advanced lung cancer, direct surgery is not effective. It is difficult to achieve radical resection by surgery merely, and even if many patients receive surgery, they may eventually have tumor recurrence and poor survival rate. Therefore, it is necessary to explore effective perioperative neoadjuvant treatment to reduce the risk of postoperative recurrence and improve the postoperative survival rate of patients. According to the reports, PD-1/ PD-L1 immunocheckpoint inhibitor may become a new method for the treatment of lung cancer. Preliminary clinical results showed that immunotherapy combined with chemoradiotherapy provided a synergies antitumor effect. Multiple clinical results showed that serplulimab provided higher overall response rate for advanced lung cancer. However, in patients with locally advanced lung cancer, the efficacy of serplulimab combined with chemotherapy for sequential radical surgery is still unclear. The purpose of this study is to observe and evaluate the efficacy and safety of serplulimab combined with chemotherapy in the neoadjuvant therapy of resectable non-small cell lung cancer.

Начало: 16.05.2023 Край: 31.12.2030 Възраст: 18–75 г.

China Second Affiliated Hospital, School of Medicine, Zhejian NCT05882513

Активно (без набиране)

The smartNTx Trial:Telemedical Management Versus Standard Aftercare in Kidney Transplant Recipients (KTR)

Kidney Transplant Rejection Kidney Transplant Failure

The smartNTx trial: Prospective, randomized controlled trial (RCT) to investigate additional interventional telemedical management versus standard aftercare in kidney transplant recipients (KTR). STUDY PURPOSE: To demonstrate that additional interventional telemedical management will lead to a higher chance for long-term graft survival, increase adherence, quality of life (QoL), and reduce complications and healthcare costs after kidney transplantation.

Начало: 15.05.2023 Край: 30.08.2026 Възраст: 1–99 г.

Germany University of Erlangen-Nürnberg Medical School NCT05897047

Активно (без набиране)

Transforming Food System Evaluation in Mozambique

ASF Consumption

Global Alliance for Improved Nutrition (GAIN)'s "Transforming Food Systems to Improve Diet Quality and Resilience for the Most Vulnerable" program seeks to improve consumption of healthy foods by improving supply, increasing demand, and improving the enabling environment for different targeted foods in 4 countries by operating at multiple levels - individuals, households, markets, producers, and policies. RTI and local partners propose to conduct impact and process evaluations of GAIN's program tailored to the theory of change and the target foods for Mozambique. The evaluation in Mozambique will include a mix of quantitative and qualitative methods and will be guided by the RE-AIM (reach, effectiveness, adoption, implementation, and maintenance) implementation research framework.

Начало: 15.05.2023 Край: 30.11.2027 Възраст: от 18 г.

Mozambique RTI International NCT05858151

Активно (без набиране)

First Evaluation of a Craniofacial Peripheral Nerve Stimulation System in Chronic Migraine

Chronic Migraine

The purpose of this study is to demonstrate the safe use of the PRIMUS system in subjects with chronic migraine. This is a single-center, open label, prospective, early feasibility study to collect initial clinical data on the PRIMUS system for the treatment of chronic migraine.

Начало: 09.05.2023 Край: 31.12.2026 Възраст: 18–84 г.

Belgium Salvia BioElectronics NCT05858801

Активно (без набиране)

The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery

Myocardial Injury Non-cardiac Surgery Remote Ischemic Preconditioning

This is a multicentre, parallel-group, randomised, sham-controlled, observer blinded trial, assessing the efficacy of remote ischemic preconditioning on preventing myocardial injury after noncardiac surgery.

Начало: 06.05.2023 Край: 31.12.2026 Възраст: от 45 г.

China Sixth Affiliated Hospital, Sun Yat-sen University NCT05733208

Активно (без набиране) Фаза 1

POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC

Advanced Cancer Non Small Cell Lung Cancer

This clinical study is looking at the combination of two experimental drugs called tepotinib and pembrolizumab. Pembrolizumab, also known as Keytruda, is licenced and available by prescription to treat a variety of cancers. Tepotinib is currently licensed in the UK for use in non-small cell lung cancer (NCSLC) and is being investigated for this purpose. Cancer immunotherapy drugs hold great promise but still do not work for many patients. Laboratory studies on cancers that do not respond well to immunotherapy reveal that most of these tumours do not have any immune cells. This suggests that the cancer has successfully hidden itself and avoided being recognised by the immune system. This study aims to use a novel approach using a targeted drug, tepotinib, to target the gene involved with NSCLC. Tepotinib is a type of drug called a kinase inhibitor. Kinase inhibitors are a newer type of drug being used to try to treat cancers. They act by blocking some of the chemical messengers that are part of the signalling process within cancer cells that control their growth. Tepotinib is used in adults to treat NSCLC that can have certain abnormal changes in the mesenchymal-epithelial transition factor gene (MET) and which has spread and/or cannot be removed by surgery. The changes in the MET gene can make an abnormal protein which can lead to uncontrolled cell growth and cancer. By blocking this abnormal protein, tepotinib may slow or stop the cancer from growing as well as potentially shrinking the cancer. This study will include patients with and without the MET exon 14 mutations. In this clinical study, the investigators aim to test our ideas in a small number of people for the first time, specifically in those patients with cancers which do not respond to cancer immunotherapy.

Начало: 03.05.2023 Край: 09.01.2029 Възраст: от 18 г.

United Kingdom Institute of Cancer Research, United Kingdom NCT05782361

Активно (без набиране)

REsponse to Combined SONS and ONS in Chronic Cluster headachE

Chronic Cluster Headache

The purpose of this study is to demonstrate the safe use of the PRIMUS System in subjects with chronic cluster headache. This is a single-centre, open label, prospective, first in human study to collect initial clinical data on the PRIMUS system for the treatment of chronic cluster headache.

Начало: 02.05.2023 Край: 30.12.2026 Възраст: от 18 г. Устройства

Australia Salvia BioElectronics NCT05868044

1 … 212 213 214 215 216 … 240